Search

Your search keyword '"Carmona-García, M. Carmen"' showing total 6 results
Start Over Author "Carmona-García, M. Carmen" Publication Year Range Last 3 years
6 results on '"Carmona-García, M. Carmen"'

1. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

Author

Evans, Joanne S, Swallow, Judith, Hanbury, Georgina, Chung, Chris, Patel, Meera, Dettorre, Gino, Belessiotis, Katherine, Saorise, Dolly, Jones, Eleanor, Apthorp, Eleanor, Moss, Charlotte, Russell, Beth, Townsend, Sarah, Jackson, Amanda, Loizidou, Angela, Piccart, Martine, Pommeret, Fanny, Colomba-Blameble, Emeline, Prat, Aleix, Cruz, Claudia A, Reyes, Roxana, Segui, Elia, Marco-Hernández, Javier, Viladot, Margarita, Harbeck, Nadia, Wuerstlein, Rachel, Henze, Franziska, Mahner, Sven, Felip, Eudald, Scotti, Lorenza, Marrari, Andrea, Grosso, Federica, Fusco, Vittorio, Delfanti, Sara, Rossi, Maura, Zambelli, Alberto, Tondini, Carlo, Chiudinelli, Lorenzo, Franchi, Michela, Libertini, Michela, Provenzano, Salvatore, Generali, Daniele, Grisanti, Salvatore, Baggi, Alice, Tovazzi, Valeria, Ficorella, Corrado, Porzio, Giampiero, Saponara, Maristella, Filetti, Marco, Tucci, Marco, Berardi, Rossana, Cantini, Luca, Paoloni, Francesco, Guida, Annalisa, Bracarda, Sergio, Iglesias, Maria, Sanchez de Torre, Ana, Tagliamento, Marco, Cortellini, Alessio, Tabernero, Josep, Mukherjee, Uma, Salazar, Ramon, Sureda, Anna, Maluquer, Clara, Ferrante, Daniela, Bower, Mark, Sharkey, Rachel, Mirallas, Oriol, Plaja, Andrea, Cucurull, Marc, Mesia, Ricard, Dalla Pria, Alessia, Newsom-Davis, Thomas, Van Hemelrijck, Mieke, Sita-Lumsden, Ailsa, Vincenzi, Bruno, Di Fazio, Giuseppina Rita, Tonini, Giuseppe, Pantano, Francesco, Bertuzzi, Alexia, Rossi, Sabrina, Brunet, Joan, Lambertini, Matteo, Pedrazzoli, Paolo, Biello, Federica, D'Avanzo, Francesca, Lee, Alvin J X, Shawe-Taylor, Marianne, Rogers, Lucy, Murphy, Cian, Cooper, Lee, Andaleeb, Ramis, Khalique, Saira, Bawany, Samira, Ahmed, Sarah, Carmona-García, M Carmen, Fort-Culillas, Roser, Liñan, Raquel, Zoratto, Federica, Rizzo, Gianpiero, Perachino, Marta, Doonga, Kris, Gaidano, Gianluca, Bruna, Riccardo, Patriarca, Andrea, Martinez-Vila, Clara, Pérez Criado, Ignacio, Giusti, Raffaele, Mazzoni, Francesca, Antonuzzo, Lorenzo, Santoro, Armando, Parisi, Alessandro, Queirolo, Paola, Aujayeb, Avinash, Rimassa, Lorenza, Diamantis, Nikolaos, Bertulli, Rossella, Fulgenzi, Claudia A M, D'Alessio, Antonio, Ruiz-Camps, Isabel, Saoudi-Gonzalez, Nadia, Garcia Illescas, David, Medina, Irene, Fox, Laura, Gennari, Alessandra, Aguilar-Company, Juan, and Pinato, David J

Published
2023
Full Text
View/download PDF

2. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Evans, Joanne S, Swallow, Judith, Chung, Chris, Patel, Meera, Dettorre, Gino, Ottaviani, Diego, Chowdhury, Amani, Merry, Eve, Chopra, Neha, Lee, Alvin JX, Sng, Christopher CT, Yu, Tamara, Shawe-Taylor, Marianne, Bain, Hamish DC, Wong, Yien Ning Sophia, Galazi, Myria, Benafif, Sarah, Dileo, Palma, Earnshaw, Irina, Patel, Grisma, Wu, Anjui, Soosaipillai, Gehan, Cooper, Lee, Andaleeb, Ramis, Dolly, Saoirse, Apthorp, Eleanor, Srikandarajah, Krishnie, Jones, Eleanor, Van Hemelrijck, Mieke, Moss, Charlotte, Russell, Beth, Chester, John, Loizidou, Angela, Piccart, Martine, Cruz, Claudia A, Reyes, Roxana, Segui, Elia, Marco-Hernández, Javier, Viladot, Margarita, Eremiev, Simeon, Fort-Culillas, Roser, Garcia, Isabel, Liñan, Raquel, Roqué Lloveras, Ariadna, Harbeck, Nadia, Wuerstlein, Rachel, Henze, Franziska, Mahner, Sven, Felip, Eudald, Pous, Anna, D'Avanzo, Francesca, Scotti, Lorenza, Krengli, Marco, Marrari, Andrea, Delfanti, Sara, Maconi, Antonio, Betti, Marta, Tonini, Giuseppe, Di Fazio, Giuseppina Rita, Tondini, Carlo, Chiudinelli, Lorenzo, Franchi, Michela, Libertini, Michela, Bertulli, Rossella, Baggi, Alice, Tovazzi, Valeria, Ficorella, Corrado, Porzio, Giampiero, Saponara, Maristella, Filetti, Marco, Zoratto, Federica, Paoloni, Francesco, Berardi, Rossana, Guida, Annalisa, Bracarda, Sergio, Iglesias, Maria, Sanchez de Torre, Ana, Tagliamento, Marco, Colomba, Emeline, Pommeret, Fanny, Pinato, David J, Aguilar-Company, Juan, Ferrante, Daniela, Hanbury, Georgina, Bower, Mark, Salazar, Ramon, Mirallas, Oriol, Sureda, Anna, Plaja, Andrea, Cucurull, Marc, Mesia, Ricard, Townsend, Sarah, Jackson, Amanda, Dalla Pria, Alessia, Newsom-Davis, Thomas, Handford, Jasmine, Sita-Lumsden, Ailsa, Vincenzi, Bruno, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Maluquer, Clara, Pedrazzoli, Paolo, Biello, Federica, Sinclair, Alasdair, Bawany, Samira, Khalique, Saira, Rossi, Sabrina, Rogers, Lucy, Murphy, Cian, Belessiotis, Katherine, Carmona-García, M Carmen, Sharkey, Rachel, García-Illescas, David, Rizzo, Gianpiero, Perachino, Marta, Saoudi-Gonzalez, Nadia, Doonga, Kris, Fox, Laura, Roldán, Elisa, Gaidano, Gianluca, Ruiz-Camps, Isabel, Bruna, Riccardo, Patriarca, Andrea, Martinez-Vila, Clara, Cantini, Luca, Zambelli, Alberto, Giusti, Raffaele, Mazzoni, Francesca, Caliman, Enrico, Santoro, Armando, Grosso, Federica, Parisi, Alessandro, Queirolo, Paola, Aujayeb, Avinash, Rimassa, Lorenza, Prat, Aleix, Tucci, Marco, Grisanti, Salvatore, Mukherjee, Uma, Diamantis, Nikolaos, Fusco, Vittorio, Generali, Daniele, Provenzano, Salvatore, Gennari, Alessandra, Tabernero, Josep, and Cortellini, Alessio

Published
2022
Full Text
View/download PDF

3. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

Author

Cortellini, Alessio, primary, Tabernero, Josep, additional, Mukherjee, Uma, additional, Salazar, Ramon, additional, Sureda, Anna, additional, Maluquer, Clara, additional, Ferrante, Daniela, additional, Bower, Mark, additional, Sharkey, Rachel, additional, Mirallas, Oriol, additional, Plaja, Andrea, additional, Cucurull, Marc, additional, Mesia, Ricard, additional, Dalla Pria, Alessia, additional, Newsom-Davis, Thomas, additional, Van Hemelrijck, Mieke, additional, Sita-Lumsden, Ailsa, additional, Apthorp, Eleanor, additional, Vincenzi, Bruno, additional, Di Fazio, Giuseppina Rita, additional, Tonini, Giuseppe, additional, Pantano, Francesco, additional, Bertuzzi, Alexia, additional, Rossi, Sabrina, additional, Brunet, Joan, additional, Lambertini, Matteo, additional, Pedrazzoli, Paolo, additional, Biello, Federica, additional, D'Avanzo, Francesca, additional, Lee, Alvin J X, additional, Shawe-Taylor, Marianne, additional, Rogers, Lucy, additional, Murphy, Cian, additional, Cooper, Lee, additional, Andaleeb, Ramis, additional, Khalique, Saira, additional, Bawany, Samira, additional, Ahmed, Sarah, additional, Carmona-García, M Carmen, additional, Fort-Culillas, Roser, additional, Liñan, Raquel, additional, Zoratto, Federica, additional, Rizzo, Gianpiero, additional, Perachino, Marta, additional, Doonga, Kris, additional, Gaidano, Gianluca, additional, Bruna, Riccardo, additional, Patriarca, Andrea, additional, Martinez-Vila, Clara, additional, Pérez Criado, Ignacio, additional, Giusti, Raffaele, additional, Mazzoni, Francesca, additional, Antonuzzo, Lorenzo, additional, Santoro, Armando, additional, Parisi, Alessandro, additional, Queirolo, Paola, additional, Aujayeb, Avinash, additional, Rimassa, Lorenza, additional, Diamantis, Nikolaos, additional, Bertulli, Rossella, additional, Fulgenzi, Claudia A M, additional, D'Alessio, Antonio, additional, Ruiz-Camps, Isabel, additional, Saoudi-Gonzalez, Nadia, additional, Garcia Illescas, David, additional, Medina, Irene, additional, Fox, Laura, additional, Gennari, Alessandra, additional, Aguilar-Company, Juan, additional, Pinato, David J, additional, Evans, Joanne S, additional, Swallow, Judith, additional, Hanbury, Georgina, additional, Chung, Chris, additional, Patel, Meera, additional, Dettorre, Gino, additional, Belessiotis, Katherine, additional, Saorise, Dolly, additional, Jones, Eleanor, additional, Moss, Charlotte, additional, Russell, Beth, additional, Townsend, Sarah, additional, Jackson, Amanda, additional, Loizidou, Angela, additional, Piccart, Martine, additional, Pommeret, Fanny, additional, Colomba-Blameble, Emeline, additional, Prat, Aleix, additional, Cruz, Claudia A, additional, Reyes, Roxana, additional, Segui, Elia, additional, Marco-Hernández, Javier, additional, Viladot, Margarita, additional, Harbeck, Nadia, additional, Wuerstlein, Rachel, additional, Henze, Franziska, additional, Mahner, Sven, additional, Felip, Eudald, additional, Scotti, Lorenza, additional, Marrari, Andrea, additional, Grosso, Federica, additional, Fusco, Vittorio, additional, Delfanti, Sara, additional, Rossi, Maura, additional, Zambelli, Alberto, additional, Tondini, Carlo, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Libertini, Michela, additional, Provenzano, Salvatore, additional, Generali, Daniele, additional, Grisanti, Salvatore, additional, Baggi, Alice, additional, Tovazzi, Valeria, additional, Ficorella, Corrado, additional, Porzio, Giampiero, additional, Saponara, Maristella, additional, Filetti, Marco, additional, Tucci, Marco, additional, Berardi, Rossana, additional, Cantini, Luca, additional, Paoloni, Francesco, additional, Guida, Annalisa, additional, Bracarda, Sergio, additional, Iglesias, Maria, additional, Sanchez de Torre, Ana, additional, and Tagliamento, Marco, additional

Published
2023
Full Text
View/download PDF

4. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Pinato, David J, primary, Aguilar-Company, Juan, additional, Ferrante, Daniela, additional, Hanbury, Georgina, additional, Bower, Mark, additional, Salazar, Ramon, additional, Mirallas, Oriol, additional, Sureda, Anna, additional, Plaja, Andrea, additional, Cucurull, Marc, additional, Mesia, Ricard, additional, Townsend, Sarah, additional, Jackson, Amanda, additional, Dalla Pria, Alessia, additional, Newsom-Davis, Thomas, additional, Handford, Jasmine, additional, Sita-Lumsden, Ailsa, additional, Apthorp, Eleanor, additional, Vincenzi, Bruno, additional, Bertuzzi, Alexia, additional, Brunet, Joan, additional, Lambertini, Matteo, additional, Maluquer, Clara, additional, Pedrazzoli, Paolo, additional, Biello, Federica, additional, Sinclair, Alasdair, additional, Bawany, Samira, additional, Khalique, Saira, additional, Rossi, Sabrina, additional, Rogers, Lucy, additional, Murphy, Cian, additional, Belessiotis, Katherine, additional, Carmona-García, M Carmen, additional, Sharkey, Rachel, additional, García-Illescas, David, additional, Rizzo, Gianpiero, additional, Perachino, Marta, additional, Saoudi-Gonzalez, Nadia, additional, Doonga, Kris, additional, Fox, Laura, additional, Roldán, Elisa, additional, Gaidano, Gianluca, additional, Ruiz-Camps, Isabel, additional, Bruna, Riccardo, additional, Patriarca, Andrea, additional, Martinez-Vila, Clara, additional, Cantini, Luca, additional, Zambelli, Alberto, additional, Giusti, Raffaele, additional, Mazzoni, Francesca, additional, Caliman, Enrico, additional, Santoro, Armando, additional, Grosso, Federica, additional, Parisi, Alessandro, additional, Queirolo, Paola, additional, Aujayeb, Avinash, additional, Rimassa, Lorenza, additional, Prat, Aleix, additional, Tucci, Marco, additional, Libertini, Michela, additional, Grisanti, Salvatore, additional, Mukherjee, Uma, additional, Diamantis, Nikolaos, additional, Fusco, Vittorio, additional, Generali, Daniele, additional, Provenzano, Salvatore, additional, Gennari, Alessandra, additional, Tabernero, Josep, additional, Cortellini, Alessio, additional, Evans, Joanne S, additional, Swallow, Judith, additional, Chung, Chris, additional, Patel, Meera, additional, Dettorre, Gino, additional, Ottaviani, Diego, additional, Chowdhury, Amani, additional, Merry, Eve, additional, Chopra, Neha, additional, Lee, Alvin JX, additional, Sng, Christopher CT, additional, Yu, Tamara, additional, Shawe-Taylor, Marianne, additional, Bain, Hamish DC, additional, Wong, Yien Ning Sophia, additional, Galazi, Myria, additional, Benafif, Sarah, additional, Dileo, Palma, additional, Earnshaw, Irina, additional, Patel, Grisma, additional, Wu, Anjui, additional, Soosaipillai, Gehan, additional, Cooper, Lee, additional, Andaleeb, Ramis, additional, Dolly, Saoirse, additional, Srikandarajah, Krishnie, additional, Jones, Eleanor, additional, Van Hemelrijck, Mieke, additional, Moss, Charlotte, additional, Russell, Beth, additional, Chester, John, additional, Loizidou, Angela, additional, Piccart, Martine, additional, Cruz, Claudia A, additional, Reyes, Roxana, additional, Segui, Elia, additional, Marco-Hernández, Javier, additional, Viladot, Margarita, additional, Eremiev, Simeon, additional, Fort-Culillas, Roser, additional, Garcia, Isabel, additional, Liñan, Raquel, additional, Roqué Lloveras, Ariadna, additional, Harbeck, Nadia, additional, Wuerstlein, Rachel, additional, Henze, Franziska, additional, Mahner, Sven, additional, Felip, Eudald, additional, Pous, Anna, additional, D'Avanzo, Francesca, additional, Scotti, Lorenza, additional, Krengli, Marco, additional, Marrari, Andrea, additional, Delfanti, Sara, additional, Maconi, Antonio, additional, Betti, Marta, additional, Tonini, Giuseppe, additional, Di Fazio, Giuseppina Rita, additional, Tondini, Carlo, additional, Chiudinelli, Lorenzo, additional, Franchi, Michela, additional, Bertulli, Rossella, additional, Baggi, Alice, additional, Tovazzi, Valeria, additional, Ficorella, Corrado, additional, Porzio, Giampiero, additional, Saponara, Maristella, additional, Filetti, Marco, additional, Zoratto, Federica, additional, Paoloni, Francesco, additional, Berardi, Rossana, additional, Guida, Annalisa, additional, Bracarda, Sergio, additional, Iglesias, Maria, additional, Sanchez de Torre, Ana, additional, Tagliamento, Marco, additional, Colomba, Emeline, additional, and Pommeret, Fanny, additional

Published
2022
Full Text
View/download PDF

5. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry

Author

Pinato, David J., Patel, Meera, Scotti, Lorenza, Colomba, Emeline, Dolly, Saoirse, Loizidou, Angela, Chester, John, Mukherjee, Uma, Zambelli, Alberto, Dalla Pria, Alessia, Aguilar-Company, Juan, Bower, Mark, Salazar, Ramon, Bertuzzi, Alexia, Brunet, Joan, Lambertini, Matteo, Tagliamento, Marco, Pous, Anna, Sita-Lumsden, Ailsa, Srikandarajah, Krishnie, Colomba, Johann, Pommeret, Fanny, Seguí, Elia, Generali, Daniele, Grisanti, Salvatore, Pedrazzoli, Paolo, Rizzo, Gianpiero, Libertini, Michela, Moss, Charlotte, Evans, Joanne S., Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Biello, Federica, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Rossi, Sabrina, Carmona-García, M. Carmen, Tondini, Carlo, Fox, Laura, Baggi, Alice, Fotia, Vittoria, Parisi, Alessandro, Porzio, Giampero, Queirolo, Paola, Cruz, Claudia Andrea, Saoudi-Gonzalez, Nadia, Felip, Eudald, Roqué Lloveras, Ariadna, Newsom-Davis, Thomas, Sharkey, Rachel, Roldán, Elisa, Reyes, Roxana, Zoratto, Federica, Earnshaw, Irina, Ferrante, Daniela, Marco-Hernández, Javier, Ruiz-Camps, Isabel, Gaidano, Gianluca, Patriarca, Andrea, Bruna, Riccardo, Sureda, Anna, Martinez-Vila, Clara, Sanchez de Torre, Ana, Berardi, Rossana, Giusti, Raffaele, Mazzoni, Francesca, Guida, Annalisa, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Krengli, Marco, Santoro, Armando, Prat, Aleix, Tabernero, Josep, Van Hemelrijck, Mieke, Diamantis, Nikolaos, Gennari, Alessandra, and Cortellini, Alessio

Abstract

IMPORTANCE: Whether the severity and mortality of COVID-19 in patients with cancer have improved in terms of disease management and capacity is yet to be defined. OBJECTIVE: To test whether severity and mortality from COVID-19 among patients with cancer have improved during the course of the pandemic. DESIGN, SETTING, AND PARTICIPANTS: OnCovid is a European registry that collects data on consecutive patients with solid or hematologic cancer and COVID-19. This multicenter case series study included real-world data from 35 institutions across 6 countries (UK, Italy, Spain, France, Belgium, and Germany). This update included patients diagnosed between February 27, 2020, and February, 14, 2021. Inclusion criteria were confirmed diagnosis of SARS-CoV-2 infection and a history of solid or hematologic cancer. EXPOSURES: SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES: Deaths were differentiated at 14 days and 3 months as the 2 landmark end points. Patient characteristics and outcomes were compared by stratifying patients across 5 phases (February to March 2020, April to June 2020, July to September 2020, October to December 2020, and January to February 2021) and across 2 major outbreaks (February to June 2020 and July 2020 to February 2021). RESULTS: At data cutoff, 2795 consecutive patients were included, with 2634 patients eligible for analysis (median [IQR] age, 68 [18-77] years ; 52.8% men). Eligible patients demonstrated significant time-dependent improvement in 14-day case-fatality rate (CFR) with estimates of 29.8% (95% CI, 0.26-0.33) for February to March 2020; 20.3% (95% CI, 0.17-0.23) for April to June 2020; 12.5% (95% CI, 0.06-22.90) for July to September 2020; 17.2% (95% CI, 0.15-0.21) for October to December 2020; and 14.5% (95% CI, 0.09-0.21) for January to February 2021 (all P < .001) across the predefined phases. Compared with the second major outbreak, patients diagnosed in the first outbreak were more likely to be 65 years or older (974 of 1626 [60.3%] vs 564 of 1008 [56.1%]; P = .03), have at least 2 comorbidities (793 of 1626 [48.8%] vs 427 of 1008 [42.4%]; P = .001), and have advanced tumors (708 of 1626 [46.4%] vs 536 of 1008 [56.1%]; P < .001). Complications of COVID-19 were more likely to be seen (738 of 1626 [45.4%] vs 342 of 1008 [33.9%]; P < .001) and require hospitalization (969 of 1626 [59.8%] vs 418 of 1008 [42.1%]; P < .001) and anti–COVID-19 therapy (1004 of 1626 [61.7%] vs 501 of 1008 [49.7%]; P < .001) during the first major outbreak. The 14-day CFRs for the first and second major outbreaks were 25.6% (95% CI, 0.23-0.28) vs 16.2% (95% CI, 0.13-0.19; P < .001), respectively. After adjusting for country, sex, age, comorbidities, tumor stage and status, anti–COVID-19 and anticancer therapy, and COVID-19 complications, patients diagnosed in the first outbreak had an increased risk of death at 14 days (hazard ratio [HR], 1.85; 95% CI, 1.47-2.32) and 3 months (HR, 1.28; 95% CI, 1.08-1.51) compared with those diagnosed in the second outbreak. CONCLUSIONS AND RELEVANCE: The findings of this registry-based study suggest that mortality in patients with cancer diagnosed with COVID-19 has improved in Europe; this improvement may be associated with earlier diagnosis, improved management, and dynamic changes in community transmission over time.

Published
2022
Full Text
View/download PDF

6. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer.

Author

Pinato DJ, Ferrante D, Aguilar-Company J, Bower M, Salazar R, Mirallas O, Sureda A, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Lee AJX, Sng CCT, Liñan R, Rossi S, Carmona-García MC, Sharkey R, Eremiev S, Rizzo G, Bain HD, Yu T, Cruz CA, Perachino M, Saoudi-Gonzalez N, Fort-Culillas R, Doonga K, Fox L, Roldán E, Zoratto F, Gaidano G, Ruiz-Camps I, Bruna R, Patriarca A, Shawe-Taylor M, Fusco V, Martinez-Vila C, Berardi R, Filetti M, Mazzoni F, Santoro A, Delfanti S, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tabernero J, Gennari A, and Cortellini A

Subjects
COVID-19 Testing, COVID-19 Vaccines, Humans, Morbidity, SARS-CoV-2, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, Neoplasms complications, Neoplasms therapy
Abstract

Background: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined., Methods: Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients., Results: 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320)., Conclusions: This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: As corresponding author of the abovementioned manuscript, I declare on behalf of my co-authors the following conflict of interests: David J Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, EISAI, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, DaVolterra and Astra Zeneca; research funding (to institution) from MSD and BMS.Aleix Prat has declared personal honoraria from Pfizer, Roche, MSD Oncology, Eli Lilly, and Daiichi Sankyo; travel, accommodations, and expenses paid by Daiichi Sankyo; research funding from Roche and Novartis; and consulting/advisory role for NanoString Technologies, Amgen, Roche, Novartis, Pfizer and Bristol-Myers Squibb.Matteo Lambertini acted as consultant for Roche, Novartis, Lilly, AstraZeneca, Exact Sciences, MSD, Pfizer, Seagen and received speaker honoraria from Roche, Novartis, Lilly, Pfizer, Takeda, Ipsen and Sandoz outside the submitted work.Joan Brunet has declared consulting/advisory role for MSD and Astra Zeneca.Alessandra Gennari has declared consulting/advisory role for Roche, MSD, Eli Lilly, Pierre Fabre, EISAI, and Daichii Sankyo; speakers bureau for Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, Astra Zeneca, Celgene, and Daichii Sankyo; research funds: EISAI, Eli Lilly, and Roche. CMV has received travel grants and other honoraria from BMS, MSD, Novartis and Roche.Gianluca Gaidano has declared consulting/advisory role for Janssen, Abbvie, Astra-Zeneca and BeiGene, and speaker fees from Janssen and Abbvie.Lorenza Rimassa received consulting fees from Taiho Oncology, Servier, Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Zymeworks; lecture fees from AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, Sanofi; travel expenses from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks.Joseph Tabernero reported consulting fees from Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc. He also reported speaker's fees from Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). He also declared institutional research support from Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Janssen-Cilag SA, MedImmune, Menarini, Merck Health KGAA, Merck Sharp & Dohme, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Pharma Mar, Sanofi Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc, Spanish Association Against Cancer Scientific Foundation and Cancer Research UK.Alessio Cortellini received consulting fees from MSD, BMS, AstraZeneca, Roche; speakers' fee from AstraZeneca, MSD, Novartis and Eisai.All remaining authors have declared no conflicts of interest.London, April 18th, 2022., (Copyright © 2022 Elsevier Ltd. All rights reserved.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results